Skinning up? Sinclair IS raises £9m for Valeant derma rights
This article was originally published in Scrip
Executive Summary
Sinclair IS Pharma is paying £9.0 million up front for distribution rights in Western Europe to certain products belonging to Valeant Pharmaceuticals that together generated revenues of £9.1 million in 2011 in that territory. Sinclair IS will also make additional sales-based royalty payments over the life of the exclusive 100 year agreement.